The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Osteogenesis imperfecta: advancements in genetics and treatment
Open accessAbstract
Purpose of review: The purpose of this review is to outline the current understanding of the molecular mechanisms and natural history of osteogenesis imperfecta, and to describe the development of new treatments for this disorder. Recent findings: The introduction of next-generation sequencing technology has led to better understanding of the genetic cause of osteogenesis imperfecta and enabled cost-effective and timely diagnosis via expanded gene panels and exome or genome sequencing. Clinically, despite genetic heterogeneity, different forms of osteogenesis imperfecta share similar features that include connective tissue and systemic manifestations in addition to bone fragility. Thus, the goals of treatment in osteogenesis imperfecta extend beyond decreasing the risk of fracture, to include the maximization of growth and mobility, and the management of extraskeletal complications. The standard of care in pediatric patients is bisphosphonates therapy. Ongoing preclinical studies in osteogenesis imperfecta mouse models and clinical studies in individuals with osteogenesis imperfecta have been instrumental in the development of new and targeted therapeutic approaches, such as sclerostin inhibition and transforming growth factor-β inhibition. Summary: Osteogenesis imperfecta is a skeletal dysplasia characterized by bone fragility and extraskeletal manifestations. Better understanding of the mechanisms of osteogenesis imperfecta will enable the development of much needed targeted therapies to improve the outcome in affected individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marini, J. C., Forlino, A., Bächinger, H. P., Bishop, N. J., Byers, P. H., Paepe, A. D., Fassier, F., Fratzl-Zelman, N., Kozloff, K. M., Krakow, D., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.52 · Cited by 842
Cited by
Marom, R., Rabenhorst, B. M., & Morello, R. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0299 · Cited by 263
Self-citationStein, M., Elefteriou, F., Busse, B., Fiedler, I. A., Kwon, R. Y., Farrell, E., Ahmad, M., Ignatius, A., Grover, L., Geris, L., et al. (2023) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4868 · Cited by 42
“Successful examples include the various forms of chondrodysplasia (for which antagonists of activated FGFR3 or downstream pathways are now clinically tested), hypophosphatemia (now successfully treated with a recombinant form of alkaline phosphatase), fibrodysplasia ossificans, or osteogenesis imperfecta.((132-134)) I…”
Background
Metadata
- Authors
- Rossi, V., Lee, B., & Marom, R.
- Venue
- Current Opinion in Pediatrics
- Published
- 2019-12
- Volume
- 31
- Issue
- 6
- Pages
- 708-715
- ISSN
- 1040-8703 (ISSN-L)
- 1531-698X
- OpenAlex
- W2966447228
- Cited by
- 172
- References
- 1
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteogenesis imperfecta: advancements in genetics and treatment. https://app.cochat.ai/papers/10.1097/mop.0000000000000813
- The paper
- Rossi, V., Lee, B., & Marom, R. (2019). Osteogenesis imperfecta: advancements in genetics and treatment. Current Opinion in Pediatrics. https://doi.org/10.1097/mop.0000000000000813
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.